IP Library Granted Patent US 8,921,530
Granted Patent B2
US 8,921,530 · App. 13/914,164 · Granted Dec 30, 2014

Method for the production of proteins

Inventor: Janus Krarup (Gentofte, DK)
Assignee: Novo Nordisk Healthcare AG
C12N9/6424
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,921,530
App. No.
13/914,164
Granted
Dec 30, 2014
Kind
B2
Abstract

The present invention relates to a process for the purification of a protease.

Claims (16)

1. A method for purification of a gamma-carboxy-glutamic (GLA)-residue containing serine protease in solution, wherein the GLA-residue containing serine protease is a recombinant Factor IX polypeptide, the method comprising:

subjecting the solution to one or more purification steps selected from the group consisting of anion exchange chromatography, hydrophobic interaction chromatography, immunoaffinity purification, size exclusion chromatography, diafiltration, and ultrafiltration,

adjusting calcium in the solution to obtain a molar ratio of free calcium ions and Factor IX polypeptide (Ca2+:FIX polypeptide) lower than 0.5; and

adjusting the pH of the solution to a value between 4.5 and 6.9 or to a value between 8.6 and 10.

2. The method according to claim 1 , wherein the molar ratio of free calcium ions and Factor IX polypeptide (Ca 2+ :FIX polypeptide) is lower than 0.45.

3. The method according to claim 1 , wherein the GLA-residue containing serine protease is purified in the presence of a divalent metal ion chelator.

4. The method according to claim 1 , wherein the molar ratio of free calcium ions and Factor IX polypeptide (Ca 2+ :FIX polypeptide) is lower than 0.40.

5. The method according to claim 1 , wherein the molar ratio of free calcium ions and Factor IX polypeptide (Ca 2+ :FIX polypeptide) is lower than 0.35.

6. The method according to claim 1 , wherein the molar ratio of free calcium ions and Factor IX polypeptide (Ca 2+ :FIX polypeptide) is lower than 0.30.

7. The method according to claim 1 , wherein the molar ratio of free calcium ions and Factor IX polypeptide (Ca 2+ :FIX polypeptide) is lower than 0.25.

8. The method according to claim 1 , wherein the molar ratio of free calcium ions and Factor IX polypeptide (Ca 2+ :FIX polypeptide) is lower than 0.20.

9. The method according to claim 1 , wherein the molar ratio of free calcium ions and Factor IX polypeptide (Ca 2+ :FIX polypeptide) is lower than 0.15.

10. The method according to claim 1 , wherein the molar ratio of free calcium ions and Factor IX polypeptide (Ca 2+ :FIX polypeptide) is lower than 0.10.

11. The method according to claim 1 , wherein the molar ratio of free calcium ions and Factor IX polypeptide (Ca 2+ :FIX polypeptide) is lower than 0.05.

12. The method according to claim 1 , wherein the Factor IX polypeptide is purified at a pH between 4.5 and 6.9.

13. The method according to claim 1 , wherein the Factor IX polypeptide is purified at a pH between 8.6 and 10.

Assignments (1)
CHANGE OF ADDRESS OF ASSIGNEE Recorded Nov 15, 2021
From: NOVO NORDISK HEALTHCARE A/G
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 058122/0546 →
Continuity (5)
Continuation 12972760 · Dec 20, 2010
Division 11229428 · Sep 15, 2005
Continuation PCTDK2004000183 · Mar 18, 2004
Provisional Application 60457809 · Mar 26, 2003
Related Publication 20130260439A1 · Oct 3, 2013